vs
FIRST BANCORP（FBP）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
FIRST BANCORP的季度营收约是Orthofix Medical Inc.的1.2倍（$257.2M vs $219.9M），FIRST BANCORP净利率更高（33.9% vs -1.0%，领先34.9%），FIRST BANCORP同比增速更快（6.5% vs 2.0%），FIRST BANCORP自由现金流更多（$103.2M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 5.6%）
第一中西部银行总部位于美国伊利诺伊州芝加哥市，地处奥黑尔机场东侧，其前身可追溯至伊利诺伊州乔利埃特市。发展至今，该行服务范围覆盖芝加哥众多郊区，包括印第安纳州西北部、伊利诺伊州南部、威斯康星州东南部以及含爱荷华州在内的四城地区，是美国规模最大的银行机构之一。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FBP vs OFIX — 直观对比
营收规模更大
FBP
是对方的1.2倍
$219.9M
营收增速更快
FBP
高出4.5%
2.0%
净利率更高
FBP
高出34.9%
-1.0%
自由现金流更多
FBP
多$86.4M
$16.8M
两年增速更快
OFIX
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $257.2M | $219.9M |
| 净利润 | $87.1M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 41.7% | 0.2% |
| 净利率 | 33.9% | -1.0% |
| 营收同比 | 6.5% | 2.0% |
| 净利润同比 | 15.1% | 92.4% |
| 每股收益（稀释后） | $0.55 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FBPOFIX
| Q4 25 | $257.2M | $219.9M | ||
| Q3 25 | $248.7M | $205.6M | ||
| Q2 25 | $246.8M | $203.1M | ||
| Q1 25 | $248.1M | $193.6M | ||
| Q4 24 | $241.5M | $215.7M | ||
| Q3 24 | $234.6M | $196.6M | ||
| Q2 24 | $231.7M | $198.6M | ||
| Q1 24 | $230.5M | $188.6M |
净利润FBPOFIX
| Q4 25 | $87.1M | $-2.2M | ||
| Q3 25 | $100.5M | $-22.8M | ||
| Q2 25 | $80.2M | $-14.1M | ||
| Q1 25 | $77.1M | $-53.1M | ||
| Q4 24 | $75.7M | $-29.1M | ||
| Q3 24 | $73.7M | $-27.4M | ||
| Q2 24 | $75.8M | $-33.4M | ||
| Q1 24 | $73.5M | $-36.0M |
毛利率FBPOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率FBPOFIX
| Q4 25 | 41.7% | 0.2% | ||
| Q3 25 | 42.7% | -8.3% | ||
| Q2 25 | 41.7% | -7.9% | ||
| Q1 25 | 40.4% | -25.2% | ||
| Q4 24 | 39.8% | -5.3% | ||
| Q3 24 | 41.1% | -9.6% | ||
| Q2 24 | 43.8% | -12.5% | ||
| Q1 24 | 42.3% | -15.6% |
净利率FBPOFIX
| Q4 25 | 33.9% | -1.0% | ||
| Q3 25 | 40.4% | -11.1% | ||
| Q2 25 | 32.5% | -6.9% | ||
| Q1 25 | 31.1% | -27.4% | ||
| Q4 24 | 31.4% | -13.5% | ||
| Q3 24 | 31.4% | -13.9% | ||
| Q2 24 | 32.7% | -16.8% | ||
| Q1 24 | 31.9% | -19.1% |
每股收益（稀释后）FBPOFIX
| Q4 25 | $0.55 | $-0.05 | ||
| Q3 25 | $0.63 | $-0.57 | ||
| Q2 25 | $0.50 | $-0.36 | ||
| Q1 25 | $0.47 | $-1.35 | ||
| Q4 24 | $0.46 | $-0.76 | ||
| Q3 24 | $0.45 | $-0.71 | ||
| Q2 24 | $0.46 | $-0.88 | ||
| Q1 24 | $0.44 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | $290.0M | — |
| 股东权益账面价值 | $2.0B | $450.0M |
| 总资产 | $19.1B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资FBPOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务FBPOFIX
| Q4 25 | $290.0M | — | ||
| Q3 25 | $290.0M | $157.2M | ||
| Q2 25 | $320.0M | $157.0M | ||
| Q1 25 | $331.1M | $156.9M | ||
| Q4 24 | $561.7M | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益FBPOFIX
| Q4 25 | $2.0B | $450.0M | ||
| Q3 25 | $1.9B | $442.5M | ||
| Q2 25 | $1.8B | $458.3M | ||
| Q1 25 | $1.8B | $458.3M | ||
| Q4 24 | $1.7B | $503.1M | ||
| Q3 24 | $1.7B | $525.9M | ||
| Q2 24 | $1.5B | $546.0M | ||
| Q1 24 | $1.5B | $570.3M |
总资产FBPOFIX
| Q4 25 | $19.1B | $850.6M | ||
| Q3 25 | $19.3B | $832.6M | ||
| Q2 25 | $18.9B | $837.2M | ||
| Q1 25 | $19.1B | $823.1M | ||
| Q4 24 | $19.3B | $893.3M | ||
| Q3 24 | $18.9B | $867.9M | ||
| Q2 24 | $18.9B | $882.0M | ||
| Q1 24 | $18.9B | $906.0M |
负债/权益比FBPOFIX
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.15× | 0.36× | ||
| Q2 25 | 0.17× | 0.34× | ||
| Q1 25 | 0.19× | 0.34× | ||
| Q4 24 | 0.34× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $107.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $103.2M | $16.8M |
| 自由现金流率自由现金流/营收 | 40.1% | 7.6% |
| 资本支出强度资本支出/营收 | 1.6% | 4.9% |
| 现金转化率经营现金流/净利润 | 1.23× | — |
| 过去12个月自由现金流最近4个季度 | $437.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FBPOFIX
| Q4 25 | $107.3M | $27.7M | ||
| Q3 25 | $137.6M | $12.4M | ||
| Q2 25 | $95.4M | $11.6M | ||
| Q1 25 | $108.2M | $-18.4M | ||
| Q4 24 | $96.8M | $23.7M | ||
| Q3 24 | $118.0M | $11.7M | ||
| Q2 24 | $71.1M | $9.0M | ||
| Q1 24 | $118.2M | $-18.6M |
自由现金流FBPOFIX
| Q4 25 | $103.2M | $16.8M | ||
| Q3 25 | $134.8M | $2.5M | ||
| Q2 25 | $92.8M | $4.5M | ||
| Q1 25 | $106.7M | $-25.1M | ||
| Q4 24 | $95.2M | $15.2M | ||
| Q3 24 | $115.4M | $6.3M | ||
| Q2 24 | $69.4M | $-360.0K | ||
| Q1 24 | $114.1M | $-29.1M |
自由现金流率FBPOFIX
| Q4 25 | 40.1% | 7.6% | ||
| Q3 25 | 54.2% | 1.2% | ||
| Q2 25 | 37.6% | 2.2% | ||
| Q1 25 | 43.0% | -13.0% | ||
| Q4 24 | 39.4% | 7.0% | ||
| Q3 24 | 49.2% | 3.2% | ||
| Q2 24 | 30.0% | -0.2% | ||
| Q1 24 | 49.5% | -15.4% |
资本支出强度FBPOFIX
| Q4 25 | 1.6% | 4.9% | ||
| Q3 25 | 1.2% | 4.8% | ||
| Q2 25 | 1.1% | 3.5% | ||
| Q1 25 | 0.6% | 3.5% | ||
| Q4 24 | 0.7% | 4.0% | ||
| Q3 24 | 1.1% | 2.7% | ||
| Q2 24 | 0.7% | 4.7% | ||
| Q1 24 | 1.8% | 5.6% |
现金转化率FBPOFIX
| Q4 25 | 1.23× | — | ||
| Q3 25 | 1.37× | — | ||
| Q2 25 | 1.19× | — | ||
| Q1 25 | 1.40× | — | ||
| Q4 24 | 1.28× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.61× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FBP
| Consumer Retail Banking Segment | $171.5M | 67% |
| Commercial And Corporate Segment | $46.9M | 18% |
| Mortgage Banking Segment | $22.4M | 9% |
| Virgin Islands Operations Segment | $18.6M | 7% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
